Navigation Links
Colorectal cancer patients with gene mutation show better response to cancer agent
Date:10/26/2010

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA.

"Recent retrospective correlative analyses of metastatic colorectal cancer trials indicate that patients with KRAS-mutated tumors do not benefit from the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab," the authors write. However, they add there are indications that not all KRAS mutations are equal in their biological characteristics, including anecdotal reports indicating that a minority of patients with KRAS-mutated tumors can respond to anti-EGFR therapy.

Wendy De Roock, M.D., of the University of Leuven, Leuven, Belgium, and colleagues conducted a study to examine whether a certain KRAS mutation (p.G13D) may be associated with a better outcome after cetuximab treatment than observed with other KRAS mutations. The study included a pooled data set of 579 patients with chemotherapy-refractory (not responsive to treatment) colorectal cancer treated with cetuximab between 2001 and 2008 and who were included in other clinical trials or received off-study treatment. Various analyses of the data were performed. The main efficacy outcome measure was overall survival; secondary efficacy measures were response rate and progression-free survival.

The researchers found that among patients who received any cetuximab-based treatment (cetuximab monotherapy or cetuximab plus chemotherapy) (n = 571), overall and progression-free survival were significantly longer in patients with p.G13D-mutated tumors (overall survival: n=32; median [midpoint], 7.6 months; progression-free survival, n = 32; median, 4.0 months) than in patients with other KRAS-mutated tumors (overall survival: median, 5.7 months; progression-free survival: median, 1.9 months).

"In a large, retrospective pooled exploratory analysis of patients with chemotherapy-refractory colorectal cancer, we show for the first time that there is a positive association between KRAS p.G13D mutations and cetuximab treatment in regard to better overall and progression-free survival," the authors write. They add this effect may not be due to a real reduction in tumor burden but to a delay in progression.

"Prospective randomized trials are needed before conclusions about potential beneficial effects of cetuximab in p.G13D-mutated chemotherapy-refractory metastatic colorectal cancer should be inferred."


'/>"/>

Contact: Sabine Tejpar, M.D., Ph.D.
sabine.tejpar@uzleuven.be
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Colorectal cancer screening can be expanded by offering it during mammography visits
2. Virtual colonoscopy option could improve colorectal cancer screening rates, patient survey suggests
3. Virtual colonoscopy and teleradiology bring colorectal cancer screening to patients in rural areas
4. Type 2 diabetes and insulin use are associated with colorectal cancer in men
5. Notable racial disparities in diagnosis, treatment and outcomes of colorectal cancer
6. Lack of insurance coverage remains obstacle to wider colorectal cancer screening with CT colonography
7. Colorectal cancer screening in Canada is cost-effective
8. Could Hot Weather Affect Results of a Colorectal Cancer Test?
9. Smoking-related colorectal cancer in older women is associated with molecularly defined DNA changes
10. Smoking-related colorectal cancer in older women is associated with molecularly-defined DNA changes
11. Hydrophobic proteins: Potential biomarkers for colorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... ... Swissray is pleased to announce the release of the ELITE DXA, a new bone ... scan window, which is more than double that of existing bone densitometers. Historically, subjects ... an accurate total body bone density or body composition study. The ELITE DXA ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... Antonio, TX (PRWEB) , ... March 24, 2017 , ... ... new clinic which can be found at 9618 Huebner Road. The clinic is the ... PT, OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from the ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just ... EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone ... with nearly 2,000 consumers (and counting) already backing the campaign. , “We ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, Scanlan ... to announce Westchester resident Lauren C. Enea has joined the firm as an associate ... concentrate her practice in elder law, Medicaid planning and applications, and Wills, Trusts and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017 A ReportsnReports.com report says, over the ... as the global sales of Adcetris and Kadcyla have been witnessing ... drug conjugates market is driven by large number of ADC drugs ... window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company Profiles, ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA (OSE: ... complete 2016 Annual Accounts with notes. The report is attached ... the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, please ... Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media enquiries: ...
Breaking Medicine Technology: